Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Type Condition

    Rhode Island

    Search
    Rhode Island
    Show Map
    Map View
    Rhode Island

    Popular Searches

    By Condition

    Depression Clinical Trials

    Anxiety Clinical Trials

    Schizophrenia Clinical Trials

    ADHD Clinical Trials

    Bipolar Disorder Clinical Trials

    Multiple Sclerosis Clinical Trials

    Autism Clinical Trials

    Treatment Resistant Depression Clinical Trials

    Borderline Personality Disorder Clinical Trials

    Social Anxiety Disorder Clinical Trials

    Parkinson's Disease Clinical Trials

    Alzheimer's Disease Clinical Trials

    By Location

    Clinical Trials in California

    Clinical Trials in Florida

    Clinical Trials in Texas

    Clinical Trials in New York

    Clinical Trials in Ohio

    Clinical Trials in Illinois

    Clinical Trials in Pennsylvania

    Clinical Trials in Michigan

    Clinical Trials in North Carolina

    Clinical Trials in Massachusetts

    Clinical Trials in Missouri

    Clinical Trials in Minnesota

    Other People Viewed

    By Subject

    Top Glioblastoma Clinical Trials near New York, NY

    Top Prediabetes Clinical Trials

    Top Fanconi Anemia Clinical Trials

    Top Clinical Trials near Indiana

    Top Depression Clinical Trials near Denver, CO

    Top Clinical Trials near Great Neck, NY

    Top Clinical Trials near Boise, ID

    Top Lung Cancer Clinical Trials near Philadelphia, PA

    26 Arthritis Trials near Cincinnati, OH

    Top Clinical Trials near Farrell, PA

    Top Idiopathic Pulmonary Fibrosis Clinical Trials

    Top Scoliosis Clinical Trials

    By Trial

    CAR-T Cell Therapy for Acute Lymphoblastic Leukemia

    Treatment Access Strategies for Cervical Cancer in Botswana

    Buffered Lidocaine for Prostate Cancer Biopsy Pain

    Implementation Mapping for Food Insecurity

    3D Holographic Surgery Assistance for Aortic Aneurysm

    Gemcitabine + Nab-Paclitaxel for Pancreatic Cancer

    OCU410ST for Stargardt Disease

    Immunotherapy + Chemotherapy for Lung Cancer

    Vaping for Smokers' Cancer Risk

    AARC Program for Childhood Obesity

    Lymphovenous Bypass Procedure for Breast Cancer

    [212Pb]VMT-alpha-NET for Neuroendocrine Tumors

    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      199 Clinical Paid Trials near Rhode Island

      Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Degarelix + Chemotherapy for Bladder Cancer

      Providence, Rhode Island
      This study is for patients who have bladder cancer that invades into the muscle wall of the bladder. The standard treatment for patients with muscle invasive bladder cancer is to give 4 cycles of chemotherapy with the drugs cisplatin and gemcitabine, then to do an operation to remove the bladder (cystectomy). In this study, the investigators will test participants' bladder cancer to see if their bladder cancer has a receptor for testosterone inside the bladder cancer cells. If it has the testosterone receptor participants will receive a medication called Degarelix that lowers testosterone levels in the blood. Degarelix will be given during the period that participants are receiving the standard of care chemotherapy drugs gemcitabine and cisplatin. The purpose of this study is to evaluate the effects, good and bad, of adding Degarelix to standard chemotherapy for patients with bladder cancer that have the testosterone receptor.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Metastases, Cardiac Disease, Others
      Must Be Taking:Cisplatin, Gemcitabine

      32 Participants Needed

      TY-2136b for Solid Tumors

      Providence, Rhode Island
      The primary objective of this study is to evaluate the safety and tolerability of TY-2136b and to determine the recommended phase 2 dose (RP2D), with dose-escalation stage and dose-expansion stage.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Symptomatic CNS Metastases, Cardiovascular Disease, Active Infections, Others
      Must Not Be Taking:Immunosuppressants, Anti-arrhythmics, PPIs, Others

      282 Participants Needed

      ONC201 for Colorectal Cancer Prevention

      Providence, Rhode Island
      This phase I trial tests the safety, side effects, and best dose of ONC201 in preventing colorectal cancer in patients with familial adenomatous polyposis (FAP) or a history of multiple polyps. ONC201 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Lynch Syndrome, Invasive Cancer, Uncontrolled Illness, Others
      Must Not Be Taking:Investigational Agents

      36 Participants Needed

      SGR-1505 for B-Cell Lymphoma

      Providence, Rhode Island
      This trial is testing SGR-1505, a new oral drug that blocks a protein called MALT1, in patients with B-cell lymphomas that have returned or did not respond to previous treatments. The goal is to find the safest and most effective dose while also seeing how well it works against the cancer.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Immediate Cytoreductive Therapy, Invasive Malignancy, CNS Involvement, Others

      52 Participants Needed

      AGEN1571 + Immunotherapy for Cancer

      Providence, Rhode Island
      This trial is testing a new drug called AGEN1571 alone and with two other drugs in patients with advanced solid tumors. The goal is to find safe doses and see how well the drugs work. The drugs aim to either directly attack cancer cells or help the immune system fight them.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      22 Participants Needed

      Tau Tracer Comparison for Alzheimer's Disease

      Providence, Rhode Island
      This trial uses special imaging agents to help visualize harmful brain proteins in people at risk of Alzheimer's disease. The agents make these proteins glow during scans, allowing doctors to see them clearly and monitor the disease.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Age:50 - 90

      Key Eligibility Criteria

      Disqualifiers:Pregnant, Breastfeeding, Cognitive Impairment, Others

      822 Participants Needed

      Acetyl-L-Carnitine for Alcoholism

      Providence, Rhode Island
      This trial is testing whether a supplement called acetyl-L-carnitine (ALCAR) can help young people aged 14-20 with alcohol use disorder and mild depression reduce their cravings for alcohol. The study will also look at other effects like mood, sleep, and safety.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:18 - 25

      Key Eligibility Criteria

      Disqualifiers:Substance Use Disorder, Liver Disease, Others
      Must Not Be Taking:Benzodiazepines, Cocaine, Opiates, Others

      50 Participants Needed

      IDE397 for Solid Tumors

      Providence, Rhode Island
      This trial is testing IDE397, a new drug, in adults with advanced cancers that don't respond to usual treatments. The drug works by blocking a protein that cancer cells need to grow.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, CNS Malignancy, Others
      Must Not Be Taking:CYP3A4/5 Inhibitors, Inducers

      180 Participants Needed

      Emtricitabine for Alzheimer's Disease

      Providence, Rhode Island
      This is a randomized, double-blind clinical trial of a daily oral dose of 200 mg emtricitabine vs. placebo in 35 participants with biomarker-confirmed MCI or mild to moderate dementia due to Alzheimer's disease. Study duration for each subject participating in the placebo-controlled research study will be approximately 12 months (up to a 3 months Screening Period, Baseline visit (1 month), 6 months of placebo or emtricitabine dosing, and 1 month follow-up). Participants will have up to 2 months to complete all procedures for the month 6 study visit.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:50 - 85

      Key Eligibility Criteria

      Disqualifiers:Parkinson's, Schizophrenia, Bipolar, Others
      Must Be Taking:Cholinesterase Inhibitors, Memantine

      35 Participants Needed

      PBCAR0191 for Blood Cancer

      Providence, Rhode Island
      This trial tests a new therapy using specially altered immune cells in adults with certain types of blood cancers that have not responded to other treatments. The goal is to find a safe and effective amount.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:CNS Disease, Cardiovascular Disease, Others
      Must Not Be Taking:Antivirals, Immunosuppressants

      129 Participants Needed

      Dostarlimab for Advanced Cancer

      Providence, Rhode Island
      This trial is testing dostarlimab, a medicine that helps the immune system fight cancer, in patients with advanced solid tumors who have limited treatment options. It works by blocking a protein that allows cancer cells to hide from the immune system. Dostarlimab has garnered extensive interest for its ability to activate the immune system to respond to cancer cells.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled CNS Metastases, Active Autoimmune, Others
      Must Not Be Taking:Immunosuppressants, Steroids

      738 Participants Needed

      DS9051b for Adrenal and Prostate Cancer

      Providence, Rhode Island
      This FIH study is designed to assess the safety, tolerability, and preliminary efficacy signals of DS9051b in participants with ACC and mCRPC.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Pituitary Dysfunction, Autoimmune, Cardiovascular, Others
      Must Be Taking:ARPI Therapy

      40 Participants Needed

      BNT317 for Cancer

      East Providence, Rhode Island
      This is a first-in-human (FIH), open-label, multiple-site, dose escalation study which will evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of increasing doses of BNT317 in participants with advanced solid tumors.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Hypertension, Diabetes, CNS Metastases, Others
      Must Not Be Taking:CD39 Inhibitors, Live Vaccines

      39 Participants Needed

      ACR-2316 for Cancer

      Providence, Rhode Island
      This is a first in-human, Open-label Phase 1 study to assess the safety of ACR-2316 for the treatment of subjects with specific, histologically confirmed, locally advanced, recurrent or metastatic solid tumors.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Recent Therapy, Pregnancy, Others

      90 Participants Needed

      RO7567132 + Atezolizumab for Cancer

      Providence, Rhode Island
      The purpose of this study is to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary clinical activity of RO7567132 as single agent and in combination with atezolizumab. The study will enroll adult participants with selected locally advanced and/or metastatic solid tumors for whom standard therapy does not exist, or has proven to be ineffective or intolerable.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:CNS Tumors, Second Malignancy, Cardiovascular Disease, Autoimmune Disease, Others

      34 Participants Needed

      PF-07934040 + Other Anti-Cancer Therapies for Non-Small Cell Lung Cancer

      Providence, Rhode Island
      The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose. This study is seeking participants who have solid tumors (a mass of abnormal cells that forms a lump or growth in the body) that: * are advanced (cancer that doesn't disappear or stay away with treatment) and * have a KRAS gene mutation (a change in the DNA of the KRAS gene that can cause cells to grow in very high numbers). This includes (but limited to) the following cancer types: Non-Small Cell Lung Cancer (NSCLC): It's a type of lung cancer where the cells grow slowly but often spread to other parts of the body. Colorectal Cancer (CRC): This is a disease where cells in the colon (a part of large intestine) or rectum grow out of control. Pancreatic ductal adenocarcinoma (PDAC): This is a cancer that starts in the ducts of the pancreas but can spread quickly to other parts of the body. Pancreas is a long, flat gland that lies in the abdomen behind the stomach. Pancreas creates enzymes that help with digestion. It also makes hormones that can help control your blood sugar levels. All participants in this study will take the study medication (PF-07934040) as pill by mouth twice a day repeating for 21-day or 28-day cycles. Depending on which part of the study participants are enrolled into they will receive the study medication (PF-07934040 alone or in combination with other anti-cancer medications). These anti-cancer medications will be given in the study clinic by intravenous (IV) that is directly injected into the veins at various times (depending on the treatment) during the 21-day or 28-day cycle. Participants can continue to take the study medication (PF-07934040) and the combination anti-cancer therapy until their cancer is no longer responding. The study will look at the experiences of people receiving the study medicines. This will help see if the study medicines are safe and effective. Participants will be involved in this study for up to 4 years. During this time, they will come into the clinic between 1 to 4 times in each 21-day or 28-day cycle. After they have stopped taking the study medication (at about at 2 years) they will be followed for another two years to see how they are doing.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Pneumonitis, Autoimmune Disease, GI Disease, Others
      Must Not Be Taking:Steroids, Immunosuppressants

      330 Participants Needed

      ABBV-969 for Prostate Cancer

      Providence, Rhode Island
      Prostate cancer has the second highest incidence rate and is the fifth leading cause of cancer-related deaths among men worldwide. The purpose of this study is to assess safety, pharmacokinetics, and efficacy of ABBV-969 as a monotherapy. ABBV-969 is an investigational drug being developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). There are parts to this study. Participants will receive ABBV-969 as a single agent at different doses. Approximately 140 adult participants will be enrolled in the study across sites worldwide. In part 1 (dose escalation), ABBV-969 will be intravenously infused in escalating doses as a monotherapy. In part 2, multiple doses will be selected from Part 1 and mCRPC participants will be assigned to one of these doses in a randomized fashion to determine the recommended Phase 2 dose. The estimated duration of the study is up to 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Other Active Malignancy, Interstitial Lung Disease, Others
      Must Be Taking:Novel Hormonal Agents

      140 Participants Needed

      NM32-2668 for Advanced Cancer

      Providence, Rhode Island
      This is a first-in-human, open-label, multi-center, Phase 1, dose-escalation study with expansion cohorts to evaluate NM32-2668 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose, define the pharmacokinetics, to explore the pharmacodynamics, and to obtain preliminary evidence of the clinical activity in adult patients with selected advanced solid tumors.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:CAR Therapy, Recent Radiotherapy, Others
      Must Not Be Taking:ROR1 Agents, CD3 Therapies

      180 Participants Needed

      DF6215 for Solid Tumors

      Providence, Rhode Island
      This trial tests a modified protein that helps the immune system fight cancer in patients with solid tumors by making it easier for immune cells to find and destroy cancer cells.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Organ Transplant, Others
      Must Not Be Taking:Chemotherapy, Radiotherapy, Immunosuppressants, Others

      255 Participants Needed

      ABBV-400 for Advanced Cancer

      Providence, Rhode Island
      This trial tests ABBV-400, a new drug, on adults with difficult-to-treat cancers. The goal is to see how safe it is and how well it works. Patients will be monitored frequently.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Interstitial Lung Disease, Untreated Brain Metastases, Others
      Must Not Be Taking:Chemotherapy, Immunotherapy, Biologics, Others

      285 Participants Needed

      Why Other Patients Applied

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51
      Match to a Trial

      M1774 + ZEN-3694 for Ovarian and Endometrial Cancer

      Providence, Rhode Island
      This phase Ib trial tests the safety, side effects, and best dose of M1774 when given with ZEN-3694 in treating patients with ovarian and endometrial cancer that has come back (recurrent). M1774 and ZEN-3694 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. M1774 and ZEN-3694 combined together has demonstrated to be better than either drug alone in killing ovarian tumor cells.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Breastfeeding, Genetic Disorders, Others
      Must Not Be Taking:Proton Pump Inhibitors, CYP3A4 Inhibitors

      60 Participants Needed

      AZD5305 + Darolutamide for Prostate Cancer

      Providence, Rhode Island
      A Study to Investigate the Biological Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men with Newly Diagnosed Prostate Cancer (ASCERTAIN).
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Severe Diseases, Cardiac Issues, Others
      Must Not Be Taking:QT Drugs, CYP3A4 Drugs

      120 Participants Needed

      INCA33890 for Metastatic Cancer

      Providence, Rhode Island
      This trial is testing a new drug called INCA33890 to see if it is safe and how well patients can tolerate it. The study focuses on people with advanced or metastatic solid tumors, which are cancers that have spread and are hard to treat. Researchers aim to find the highest dose that can be given without causing serious side effects.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Other Malignancy, Cardiac Disease, Others
      Must Not Be Taking:Systemic Steroids, Anticoagulants

      408 Participants Needed

      LYT-200 for Acute Myeloid Leukemia and Preleukemia

      Providence, Rhode Island
      A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), or with Relapsed/refractory, High-risk Myelodysplastic Syndrome (MDS)
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Acute Promyelocytic Leukemia, Active Tumors, Others
      Must Not Be Taking:Immunosuppressants

      90 Participants Needed

      JANX008 for Advanced Cancer

      Providence, Rhode Island
      This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic carcinoma expressing EGFR.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Cardiovascular Diseases, Active Infection, Others
      Must Not Be Taking:EGFR-targeted, CD3 Engaging

      130 Participants Needed

      DS-1103a + T-DXd for Advanced Cancer

      Providence, Rhode Island
      This study will evaluate the safety and efficacy of DS-1103a combination therapy in patients with advanced solid tumors.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Myocardial Infarction, ILD, CNS Metastases, Others
      Must Not Be Taking:Corticosteroids, Immunosuppressives

      78 Participants Needed

      PYX-201 for Solid Tumors

      Providence, Rhode Island
      This trial is testing PYX-201, a new drug, to find the best dose for patients whose solid tumors have returned or didn't respond to other treatments. The drug aims to either kill cancer cells or boost the immune system to fight the cancer.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Cardiovascular Disease, Active Infections, Others

      330 Participants Needed

      PYX-106 for Solid Tumors

      Providence, Rhode Island
      The primary objective of this study is to determine the recommended dose(s) of PYX-106 in participants with relapsed/refractory solid tumors.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Peripheral Neuropathy, Others
      Must Not Be Taking:Steroids, Others

      47 Participants Needed

      AZD9592 for Solid Tumors

      Providence, Rhode Island
      This trial is testing a new drug called AZD9592 in patients with advanced solid tumors. The goal is to see if AZD9592 can help treat these cancers, either on its own or with other treatments. Researchers are looking at how safe the drug is, how well patients tolerate it, and if it can shrink or stop the growth of tumors.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:ILD/pneumonitis, Spinal Cord Compression, Active Infection, Brain Metastases, Cardiac Comorbidities, Others
      Must Not Be Taking:Corticosteroids

      403 Participants Needed

      IMGN151 for Ovarian Cancer

      Providence, Rhode Island
      This trial is testing IMGN151, a new drug, in adults with certain recurrent cancers to see if it is safe, how the body handles it, if it causes immune reactions, and if it can help fight the cancer.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Ocular Disorders, Cardiac Disease, Stroke, Others

      423 Participants Needed

      1...345...7

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do clinical trials in Rhode Island pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do clinical trials in Rhode Island work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in Rhode Island 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Rhode Island is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Rhode Island several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a medical study in Rhode Island?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest clinical trials in Rhode Island?

      Most recently, we added Imiquimod Cream for Basal Cell Carcinoma, DS9051b for Adrenal and Prostate Cancer and NovoTTF-200A + Pembrolizumab for Melanoma to the Power online platform.